SCHEMBL17208943

SCHEMBL17208943

CCc1cc2ccc(C)cc2cc1C#N

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PKM P14618 2/20 0.47
▸ CYP2A6 P11509 3/20 0.45
▸ CYP1A2 P05177 2/20 0.45
▸ MAPT P10636 6/20 0.41
▸ RXFP1 Q9HBX9 2/20 0.41
▸ SMN1; SMN2 Q16637 5/20 0.41
▸ NPC1 O15118 4/20 0.41
▸ RAB9A P51151 4/20 0.41
▸ HSD17B10 Q99714 3/20 0.41
▸ NFKB1 P19838 2/20 0.41
▸ NFKB2 Q00653 2/20 0.41
▸ RELA Q04206 2/20 0.41
▸ TSHR P16473 2/20 0.41
▸ HBB P68871 1/20 0.41
▸ L3MBTL1 Q9Y468 1/20 0.41
▸ PDE3B Q13370 1/20 0.40
▸ PDE3A Q14432 1/20 0.40
▸ KDM4E B2RXH2 4/20 0.40
▸ GAA P10253 1/20 0.40
▸ NPSR1 Q6W5P4 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13347773 0.83 CYP2A6 (0.59) PKMCYP2A6CYP1A2MAPTRXFP1
SCHEMBL8237072 0.80 AR (0.42) PKMCYP2A6MAPTSMN1; SMN2NPC1
SCHEMBL13462475 0.80 PDE3B (0.45) PKMCYP2A6MAPTRXFP1SMN1; SMN2
SCHEMBL8404530 0.78 CYP2A6 (0.52) PKMCYP2A6CYP1A2MAPTRXFP1
SCHEMBL14525472 0.75 CYP2A6 (0.48) PKMCYP2A6CYP1A2RXFP1TSHR
SCHEMBL2153696 0.74 PDE3B (0.41) CYP2A6MAPTRXFP1HSD17B10TSHR
SCHEMBL17208935 0.73 CYP2A6 (0.50) CYP2A6CYP1A2MAPTRXFP1SMN1; SMN2
SCHEMBL2153698 0.72 AR (0.45) PKMSMN1; SMN2TSHRL3MBTL1PDE3B
SCHEMBL15298755 0.72 AR (0.59) CYP2A6CYP1A2RXFP1KDM4EGAA
SCHEMBL23797211 0.71 L3MBTL1 (0.45) MAPTRXFP1HSD17B10TSHRL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2616460-B1 HETEROCYCLIC COMPOUNDS FOR TREATING OR PREVENTING DISORDERS CAUSED BY REDUCED NEUROTRANSMISSION OF SEROTONIN, NOREPHNEPHRINE OR DOPAMINE. OTSUKA PHARMA CO LTD (JP) 2015-10-28 — — EP disclosed
Send feedback